logo-loader
viewFSD Pharma

FSD Pharma advancing its Phase 1 study in Australia

FSD Pharma Inc (CSE:HUGE) (NASDAQ:HUGE) CEO Raza Bokhari sat down with Proactive’s Christine Corrado at BIO CEO in New York. Bokhari says the Cobourg, Ontario-based company will initiate Phase 1 safety trials in patients for its lead drug candidate PP 101 micro-PEA in before the end of 1Q, aiming to treat symptoms related to fibromyalgia, a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues.

Quick facts: FSD Pharma

Price: 4.95 CAD

CSE:HUGE
Market: CSE
Market Cap: $50.48 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

FSD Pharma raises more than C$10M in private placement, makes progress with...

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE.CN) CEO Raza Bokhari tells Proactive how the firm is planning to use its recently-raised C$10.125 million. Bokhari says the Cobourg, Ontario-headquartered company had struck agreements with institutional investors for the purchase and sale of 1.5 million of...

on 06/12/2020

2 min read